Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Therapeutic effects of nebulization- based delivery of anti-miR-146a in experimental pulmonary arterial hypertension
Session:
Posters (Sessão 2 - Écran 3) - Ciência Básica
Speaker:
Joana Gomes
Congress:
CPC 2022
Topic:
O. Basic Science
Theme:
36. Basic Science
Subtheme:
36.5 Basic Science - Vascular Diseases
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
Joana Santos-Gomes; Pedro Mendes-Ferreira; Rui Adão; Carolina Maia-Rocha; Inês Vasconcelos; Inês Gandra; Pedro Salvador; Adelino Leite-Moreira; Carmen Brás-Silva
Abstract
<p style="text-align:justify"><span style="font-size:medium"><span style="font-family:"Times New Roman",serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">Pulmonary arterial hypertension (PAH), is a chronic disorder characterized by excessive pulmonary vascular remodeling, resulting in elevated pulmonary vascular resistance and right ventricle (RV) overload and failure. PAH remains incurable, and new therapeutic approaches are required. The microRNA-146a (miR-146a) promotes vascular smooth muscle cell proliferation and vascular neointimal hyperplasia, both important hallmarks of PAH. </span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:"Times New Roman",serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">This study aimed to investigate the role of miR-146a in the pathophysiology of PAH and in the progression to RV hypertrophy and failure.</span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:"Times New Roman",serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">Male Sprague Dawley rats received a subcutaneous injection of monocrotaline, 60 mg/kg, (MCT group) or vehicle (CTRL group). Fourteen days after the injection, they were treated, by intratracheal nebulization, with an anti-miR-146a (2,5 nmol in 100 μl of sterile water) on three different days: 14, 19, and 23, forming four distinct groups: CTRL-treated; CTRL-untreated, MCT-treated, and MCT-untreated. Twenty-seven days after MCT injection, echocardiographic and invasive hemodynamic evaluations were performed in all animal groups. </span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:"Times New Roman",serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">Compared to MCT-untreated rats, the MCT-treated rats showed decreased RV hypertrophy, </span></span><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">(as </span></span><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">measured by the Fulton index</span></span><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">),</span></span><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"> decreased RV end-diastolic diameter/left ventricle end-diastolic diameter (RVEDD/LVEDD) ratio, and decreased RV diastolic pressures. </span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:medium"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><span style="font-size:11pt"><span style="font-family:Arial,sans-serif">Our findings show that miR-146a pharmacological inhibition by an anti-miR-146a, reduces RV remodeling and improves cardiac function. In this way, miR-146a can represent a promising therapeutic target in PAH. </span></span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site